BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29573330)

  • 1. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
    Kamphuisen PW; Lee AYY; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    J Thromb Haemost; 2018 Jun; 16(6):1069-1077. PubMed ID: 29573330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Bauersachs R; Lee AYY; Kamphuisen PW; Meyer G; Janas MS; Jarner MF; Khorana AA;
    Thromb Haemost; 2018 May; 118(5):914-921. PubMed ID: 29618162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
    Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
    BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.
    Sandén P; Renlund H; Svensson PJ; Själander A
    Thromb Haemost; 2017 Jan; 117(1):27-32. PubMed ID: 27652593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials.
    Laporte S; Chapelle C; Bertoletti L; Ollier E; Zufferey P; Lega JC; Merah A; Décousus H; Schulman S; Meyer G; Cucherat M; Mismetti P
    J Thromb Haemost; 2017 Aug; 15(8):1547-1558. PubMed ID: 28544422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
    Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
    Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
    J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
    Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
    Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Anderson JL; Li J; Rodriguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple B; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2019 Sep; 322(9):834-842. PubMed ID: 31479138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin.
    Nordstrom BL; Evans MA; Murphy BR; Nutescu EA; Schein JR; Bookhart BK
    Curr Med Res Opin; 2015 Mar; 31(3):439-47. PubMed ID: 25495136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin.
    Marshall AL; Campigotto F; Neuberg D; Rowe B; Connors JM
    Clin Appl Thromb Hemost; 2015 Oct; 21(7):632-8. PubMed ID: 25850917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial.
    Zhang L; Zheng X; Long Y; Wu M; Chen Y; Yang J; Liu Z; Zhang Z
    J Thromb Haemost; 2017 Oct; 15(10):1934-1941. PubMed ID: 28762606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended International Normalized Ratio testing intervals for warfarin-treated patients.
    Barnes GD; Kong X; Cole D; Haymart B; Kline-Rogers E; Almany S; Dahu M; Ekola M; Kaatz S; Kozlowski J; Froehlich JB
    J Thromb Haemost; 2018 Jul; 16(7):1307-1312. PubMed ID: 29763979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.